CY1117615T1 - Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης - Google Patents

Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης

Info

Publication number
CY1117615T1
CY1117615T1 CY20161100487T CY161100487T CY1117615T1 CY 1117615 T1 CY1117615 T1 CY 1117615T1 CY 20161100487 T CY20161100487 T CY 20161100487T CY 161100487 T CY161100487 T CY 161100487T CY 1117615 T1 CY1117615 T1 CY 1117615T1
Authority
CY
Cyprus
Prior art keywords
compounds
theiazolis
sulfonamidis
oxazolis
sulfonamide
Prior art date
Application number
CY20161100487T
Other languages
English (en)
Inventor
Jerry Leroy Adams
Scott Howard Dickerson
Neil W Johnson
Kevin Kuntz
Kimberly Petrov
Jeffrey M Ralph
Tara Renae Rheault
Gregory Schaaf
John Stellwagen
Xinrong Tian
David Edward Uehling
Alex Gregory Waterson
Brian Wilson
George Adjabeng
Keith Hornberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117615(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1117615T1 publication Critical patent/CY1117615T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις σουλφοναμιδίου θειαζόλης και σουλφοναμιδίου οξαζόλης, ενώσεις που τις περιέχουν καθώς και διαδικασίες για την παρασκευή και μεθόδους για τη χρήση τους ως φαρμακευτικούς παράγοντες.
CY20161100487T 2008-05-06 2016-06-02 Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης CY1117615T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5074408P 2008-05-06 2008-05-06
EP09743378.3A EP2282636B1 (en) 2008-05-06 2009-05-04 Benzene sulfonamide thiazole and oxazole compounds

Publications (1)

Publication Number Publication Date
CY1117615T1 true CY1117615T1 (el) 2017-04-26

Family

ID=41265326

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100487T CY1117615T1 (el) 2008-05-06 2016-06-02 Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης

Country Status (35)

Country Link
US (6) US8415345B2 (el)
EP (2) EP3106462A1 (el)
JP (1) JP5426664B2 (el)
KR (1) KR101628746B1 (el)
CN (1) CN102083312B (el)
AR (1) AR071617A1 (el)
AU (1) AU2009244491B2 (el)
BR (1) BRPI0912541B8 (el)
CA (1) CA2723396C (el)
CL (1) CL2009001065A1 (el)
CO (1) CO6321189A2 (el)
CY (1) CY1117615T1 (el)
DK (1) DK2282636T3 (el)
DO (1) DOP2010000326A (el)
EA (1) EA019349B1 (el)
ES (1) ES2576684T3 (el)
HK (1) HK1147907A1 (el)
HR (1) HRP20160447T1 (el)
HU (1) HUE028820T2 (el)
IL (1) IL209018A (el)
JO (1) JO3408B1 (el)
MA (1) MA32369B1 (el)
MX (1) MX2010012074A (el)
MY (1) MY155317A (el)
NZ (1) NZ588970A (el)
PE (1) PE20091952A1 (el)
PL (1) PL2282636T3 (el)
RS (1) RS54725B1 (el)
SG (1) SG190624A1 (el)
SI (1) SI2282636T1 (el)
TW (1) TWI432430B (el)
UA (1) UA103319C2 (el)
UY (1) UY31806A (el)
WO (1) WO2009137391A2 (el)
ZA (1) ZA201007960B (el)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
EP2265574A1 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
BRPI0908268A2 (pt) * 2008-02-29 2018-10-30 Array Biopharma Inc compostos do inibidor de raf e seus métodos de uso
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
JP2011513330A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010104899A1 (en) * 2009-03-12 2010-09-16 Glaxosmithkline Llc Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN102665418B (zh) 2009-10-08 2014-10-29 葛兰素史密斯克莱有限责任公司 组合
KR101696003B1 (ko) 2009-10-08 2017-01-13 노파르티스 아게 조합물
JP2013507442A (ja) * 2009-10-12 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
DK2488033T3 (da) 2009-10-16 2019-09-02 Novartis Ag Kombination, der omfatter en MEK-hæmmer og en B-raf-hæmmer
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
WO2011059610A1 (en) * 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
KR20120133377A (ko) * 2010-01-27 2012-12-10 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서 3,4-디아릴피아졸의 설폰아미도 유도체
US20130096149A1 (en) * 2010-06-25 2013-04-18 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012016993A1 (en) * 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
WO2012036919A2 (en) * 2010-09-14 2012-03-22 Glaxosmithkline Llc Combination of braf and vegf inhibitors
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
JP2013543008A (ja) * 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Ｂｒａｆ阻害剤による治療方法
ES2693107T3 (es) * 2011-01-25 2018-12-07 The Regents Of The University Of Michigan Inhibidores de Bcl-2/Bcl-xL para su uso en el tratamiento del cáncer
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
ES2580961T3 (es) * 2011-02-24 2016-08-30 Nerviano Medical Sciences S.R.L. Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
US8389723B1 (en) * 2011-08-24 2013-03-05 Glaxosmithkline Llc Deuterated benzene sulfonamide thiazole compounds
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SG11201401260QA (en) 2011-11-23 2014-07-30 Novartis Ag Pharmaceutical formulations
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
EP2892535B1 (en) * 2012-09-04 2021-09-22 Novartis AG Method of adjuvant cancer treatment
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
WO2014072486A1 (en) * 2012-11-09 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) New benzene sulfonamide thiazole compounds
CN103936728B (zh) * 2013-01-18 2016-08-10 通化济达医药有限公司 噻唑激酶抑制剂
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN103965180B (zh) * 2013-01-24 2016-09-07 通化济达医药有限公司 苯磺酰胺噁唑和噻唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN104109159A (zh) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
TWI634114B (zh) 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
EP3004060B1 (en) * 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
AU2014276440A1 (en) 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
WO2015003571A1 (zh) 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
CN103880831A (zh) * 2013-11-25 2014-06-25 镇江圣安医药有限公司 N-(2-氟苯基)-2,6-二氟苯磺酰胺的衍生物及其应用
US20160367662A1 (en) 2013-12-12 2016-12-22 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
JP6571665B2 (ja) 2013-12-28 2019-09-04 ガーダント ヘルス， インコーポレイテッド 遺伝的バリアントを検出するための方法およびシステム
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
WO2016038582A1 (en) * 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as raf kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016059548A1 (en) 2014-10-13 2016-04-21 Mylan Laboratories Ltd Processes for the preparation of dabrafenib
CN105651927B (zh) * 2014-11-14 2019-12-13 泰州复旦张江药业有限公司 一种伐地昔布/帕瑞昔布有关物质的rt-hplc检测方法
ES2901792T3 (es) 2015-03-31 2022-03-23 Syros Pharmaceuticals Inc Procedimientos de estratificación de pacientes para el tratamiento con agonistas del receptor del ácido retinoico
CN106366080A (zh) * 2015-07-21 2017-02-01 重庆大学 一种抗黑色素瘤的化合物及其应用
US10328065B2 (en) * 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
MX2019003095A (es) 2016-09-19 2019-07-04 Novartis Ag Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
JP2019532944A (ja) 2016-09-23 2019-11-14 セルイプセ Ｌｉｍｋ介在性疾患における、ｌｉｍキナーゼ阻害剤、医薬組成物および使用方法
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib
WO2019008487A1 (en) 2017-07-05 2019-01-10 Novartis Ag NEW PHARMACEUTICAL COMPOSITION
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
RU2020135055A (ru) 2018-03-30 2022-05-05 Новартис Аг Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
EP3823615A4 (en) * 2018-06-18 2022-04-06 Duke University COMPOSITIONS AND METHODS OF TREATMENT OF DISORDERS CHARACTERIZED BY ABERRANTE RAS/MAPK SIGNALING
EP3867409A1 (en) 2018-10-16 2021-08-25 Novartis AG Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
GB201901507D0 (en) 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
WO2021110997A1 (en) 2019-12-05 2021-06-10 INSERM (Institut National de la Santé et de la Recherche Médicale) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
KR20220148847A (ko) 2020-02-28 2022-11-07 노파르티스 아게 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
TW202146024A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合
KR102574950B1 (ko) 2020-04-30 2023-09-06 메드샤인 디스커버리 아이엔씨. 벤조술탐 함유 화합물
EP4255434A2 (en) * 2020-12-02 2023-10-11 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN112724052B (zh) * 2021-01-21 2021-09-07 南京艾美斐生物医药科技有限公司 一种gpr101蛋白受体抑制剂及其制备和应用
CN113024384A (zh) * 2021-03-16 2021-06-25 湖南工程学院 一种2-氟-3-硝基苯甲酸中间体原料的合成方法
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
CN113717053B (zh) * 2021-09-02 2023-10-27 合肥利夫生物科技有限公司 一种酪氨酸激酶抑制剂关键中间体的合成方法
WO2023070076A1 (en) * 2021-10-22 2023-04-27 The Board Of Trustees Of The University Of Illinois Compounds for cancers driven by braf mutation
US20230303509A1 (en) * 2022-03-28 2023-09-28 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240024A1 (en) * 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
CN115260179A (zh) * 2022-08-23 2022-11-01 江苏大学 一种2-氨基嘧啶衍生物及其制备方法和应用
WO2024084086A1 (en) * 2022-10-20 2024-04-25 Biper Therapeutics Sas Compositions comprising a benzene sulfonamide thiazole compound

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
KR970069028A (ko) 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
EP0891339A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507592A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250936A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9609441D0 (en) 1996-05-04 1996-07-10 Zeneca Ltd Process
AU721130B2 (en) 1996-06-28 2000-06-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US5755056A (en) 1996-07-15 1998-05-26 Remington Arms Company, Inc. Electronic firearm and process for controlling an electronic firearm
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU744475B2 (en) 1997-04-24 2002-02-28 Bristol-Myers Squibb Company Methods and compositions for use in modulating expression of matrix metalloproteinase genes
EP1510519B1 (en) 1997-09-05 2006-02-15 Glaxo Group Limited Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
CA2347741C (en) 1998-10-22 2006-12-12 F. Hoffmann-La Roche Ag Thiazole-derivatives
DE69919887T2 (de) * 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford Pyrazolopyridin derivative als selektive cox-2 inhibitoren
ATE309205T1 (de) * 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
FR2788770B1 (fr) 1999-01-21 2001-02-16 Oreal Nouveaux 2-sulfonylaminophenols cationiques, leur utilisation a titre de coupleur pour la teinture d'oxydation, compositions les comprenant et procedes de teinture
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
JP2002542280A (ja) 1999-04-27 2002-12-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な治療
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1219606A4 (en) 1999-07-19 2005-08-31 Shionogi & Co ACYLOXYMETHOXYCARBONYLE PENDANT TRICYCLIC COMPOUNDS
AU6016000A (en) 1999-07-23 2001-02-13 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
MXPA01013452A (es) 1999-07-23 2002-07-02 Shionogi & Co Inhibodores de diferenciacion th2.
MX226123B (es) 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001019798A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics Inc. INHIBITORS OF FACTOR Xa
JP2003512467A (ja) 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
BR0015532A (pt) * 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
WO2001064643A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
NZ521068A (en) 2000-03-29 2005-04-29 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
KR20030009416A (ko) 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
EP1276742B1 (en) 2000-04-28 2004-06-09 Glaxo Group Limited Process for the preparation of pyrazolopyridine derivatives
WO2001087857A1 (en) 2000-05-16 2001-11-22 Nippon Soda Co., Ltd. Phenyloxazole compounds and fungicides for agricultural and horticultural use
ATE272617T1 (de) 2000-06-13 2004-08-15 Lilly Co Eli Sulfonamid-derivate
EP1296977A1 (en) 2000-06-23 2003-04-02 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
DE60112609T2 (de) 2000-12-15 2006-01-19 Glaxo Group Ltd., Greenford Pyrazolopyridine
ES2243579T3 (es) 2000-12-15 2005-12-01 Glaxo Group Ltd Derivados de pirazolopirideno.
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
WO2002062792A1 (fr) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
AU2002247208A1 (en) 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
ATE274515T1 (de) 2001-03-08 2004-09-15 Smithkline Beecham Corp Pyrazolopyridinderivate
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
WO2002083672A1 (en) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
BR0208956A (pt) 2001-04-16 2004-07-13 Tanabe Seiyaku Co Abridor de canais de k ativados por cálcio de grande condutância
DE60204452T2 (de) 2001-04-27 2005-12-15 Smithkline Beecham Corp. Pyrazolo[1,5a]Pyridinderivate
WO2002098363A2 (en) 2001-06-06 2002-12-12 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
EP1401836B1 (en) 2001-06-21 2006-08-23 SmithKline Beecham Corporation Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
JP2005507878A (ja) 2001-09-07 2005-03-24 スミスクライン ビーチャム コーポレーション ヘルペス感染症を治療するためのピラゾロ−ピリジン類
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
DE10154125A1 (de) 2001-10-25 2003-05-22 Zeiss Carl Semiconductor Mfg Messverfahren und Messsystem zur Vermessung der Abbildungsqualität eines optischen Abbildunsgssystems
JP2005526008A (ja) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター
DE60222465T2 (de) 2001-12-11 2008-06-05 Smithkline Beecham Corp. Pyrazolopyridin-derivate als antiherpesmittel
AU2003222221A1 (en) 2002-02-15 2004-10-25 The General Hospital Corporation Map-kinase inhibitors as regulators of tumour-associated antigen expression
WO2003076441A1 (en) 2002-03-07 2003-09-18 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
CA2483500A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
AU2003228770A1 (en) 2002-05-10 2003-11-11 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
WO2005027710A2 (en) 2002-09-11 2005-03-31 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
CA2499852A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
AU2003295408A1 (en) 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US7125997B2 (en) 2002-12-20 2006-10-24 Irm Llc Differential tumor cytotoxicity compounds and compositions
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US6893159B1 (en) 2003-01-27 2005-05-17 Christopher Eugene Hosmer Lubrication free connection
AU2004218456A1 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists.
WO2004091480A2 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
BRPI0409447A (pt) 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
EP1616191A2 (en) 2003-04-14 2006-01-18 Novartis AG Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative deseases
EP1620420A2 (en) 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
EP1620422A2 (en) 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
KR20050115337A (ko) 2003-04-30 2005-12-07 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 단백질 티로신 포스파타제 ―１ｂ의 억제제로서의 치환된아미노 카르복실산
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2004110418A2 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0315517D0 (en) 2003-07-02 2003-08-06 Barrett Kevin J Earth clamp
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
CA2533870A1 (en) 2003-07-30 2005-02-10 Shudong Wang Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
EP1711497A1 (en) 2004-01-30 2006-10-18 AB Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2005090296A2 (en) 2004-03-11 2005-09-29 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
WO2005086873A2 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
CN101389345A (zh) 2004-03-19 2009-03-18 宾州研究基金会 治疗黑素瘤的组合方法和组合物
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US20050267032A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
JP2007223903A (ja) 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
CA2575359A1 (en) * 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
WO2006020767A2 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
JP2008511630A (ja) 2004-08-31 2008-04-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＴＧＦ−βインヒビターとしてのピリミジニルピラゾール
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP4810814B2 (ja) 2004-09-15 2011-11-09 オムロン株式会社 光学シート及び面光源装置
AU2005289887A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
CA2584794A1 (en) 2004-10-26 2006-05-04 Third-Order Nanotechnologies, Inc. Tricyclic spacer systems for nonlinear optical devices
US20060094747A1 (en) * 2004-10-28 2006-05-04 The Institute For Pharmaceutical Discovery, L.L.C. Substituted carboxylic acids
EP1805136A1 (en) * 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
US20060134068A1 (en) * 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
ATE542817T1 (de) 2004-11-10 2012-02-15 Ono Pharmaceutical Co Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
JP2008520573A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
AU2005307818A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
JP2008520693A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー プロテインチロシンホスファターゼ阻害剤としての置換アミノ酸
EP1844043A2 (en) 2004-11-18 2007-10-17 The Institutes for Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO2006068826A2 (en) 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US7812022B2 (en) * 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
JP5253815B2 (ja) 2005-01-14 2013-07-31 ケモセントリックス， インコーポレイテッド ヘテロアリールスルホンアミドおよびｃｃｒ２
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7880008B2 (en) 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2007003036A1 (en) 2005-06-30 2007-01-11 Streetlight Intelligence, Inc. Method and system for luminance characterization
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007009013A2 (en) 2005-07-13 2007-01-18 University Of Utah Research Foundation Methods and compositions related to a braf mutation and microsatellite stability
US7713960B2 (en) 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
US7910742B2 (en) 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
US7968572B2 (en) 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
CN101304983A (zh) 2005-11-07 2008-11-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
PL1951692T3 (pl) 2005-11-07 2011-02-28 Irm Llc Oksazolowe i tiazolowe modulatory PPAR
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE602006021776D1 (de) 2005-11-16 2011-06-16 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
ES2421450T3 (es) 2005-12-05 2013-09-02 Glaxosmithkline Llc 2-Pirimidinil-pirazolopiridinas inhibidoras de la quinasa ErbB
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
TW200740803A (en) 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CA2637658C (en) 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use
US20070275960A1 (en) 2006-01-25 2007-11-29 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
US20070219239A1 (en) 2006-02-10 2007-09-20 Mjalli Adnan M Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
US7713978B2 (en) * 2006-03-31 2010-05-11 Nigel Paul King Compounds
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
EP2007716A1 (en) * 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
AU2006342509A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008013660A2 (en) 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
WO2008013928A2 (en) 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2420494B1 (en) * 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
GB0622202D0 (en) 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
AU2007333377B2 (en) 2006-12-08 2014-01-16 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
KR20090088962A (ko) 2006-12-15 2009-08-20 바이엘 쉐링 파마 악티엔게젤샤프트 ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도
EP2120580B1 (en) 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9556491B2 (en) 2007-02-26 2017-01-31 John Wayne Cancer Institute Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
AU2008222807A1 (en) * 2007-03-08 2008-09-12 Plexxikon, Inc. PPAR active compounds
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
ES2400619T3 (es) * 2007-06-01 2013-04-11 Glaxosmithkline Llc Inhibidores de imidazopiridina quinasa
CN107021895A (zh) 2007-06-12 2017-08-08 尔察祯有限公司 抗菌剂
US20100240657A1 (en) 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
CA2699290C (en) 2007-09-11 2018-05-15 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
AU2008323698A1 (en) 2007-11-09 2009-05-14 John Wayne Cancer Institute Utility of RET mutant in diagnosis and treatment of melanoma
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
WO2009076140A1 (en) 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
AR069700A1 (es) 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
WO2009096198A1 (ja) 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
WO2009100214A2 (en) 2008-02-05 2009-08-13 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2303013A1 (en) 2008-07-07 2011-04-06 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
EP2331095B1 (en) 2008-08-04 2014-10-15 CHDI Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
JP2012500013A (ja) 2008-08-18 2012-01-05 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． Ｈｓｐ９０阻害剤に対する感受性
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
US8499305B2 (en) 2010-10-15 2013-07-30 Via Technologies, Inc. Systems and methods for performing multi-program general purpose shader kickoff

Also Published As

Publication number Publication date
PE20091952A1 (es) 2010-01-21
MY155317A (en) 2015-09-30
AU2009244491A1 (en) 2009-11-12
US7994185B2 (en) 2011-08-09
WO2009137391A3 (en) 2009-12-30
UY31806A (es) 2009-12-14
US8642759B2 (en) 2014-02-04
MX2010012074A (es) 2011-03-21
CA2723396C (en) 2013-09-10
HUE028820T2 (en) 2017-01-30
IL209018A0 (en) 2011-01-31
AR071617A1 (es) 2010-06-30
CN102083312A (zh) 2011-06-01
RS54725B1 (sr) 2016-10-31
KR101628746B1 (ko) 2016-06-13
JP5426664B2 (ja) 2014-02-26
EA019349B1 (ru) 2014-03-31
EP2282636A2 (en) 2011-02-16
US20090298815A1 (en) 2009-12-03
NZ588970A (en) 2012-06-29
HRP20160447T1 (hr) 2016-05-20
BRPI0912541B8 (pt) 2021-05-25
EP3106462A1 (en) 2016-12-21
BRPI0912541A2 (pt) 2020-08-04
ZA201007960B (en) 2012-04-25
TWI432430B (zh) 2014-04-01
DK2282636T3 (en) 2016-05-02
JP2011519940A (ja) 2011-07-14
WO2009137391A2 (en) 2009-11-12
US20160068523A1 (en) 2016-03-10
PL2282636T3 (pl) 2016-08-31
US20110172215A1 (en) 2011-07-14
EA201001680A1 (ru) 2011-06-30
US9233956B2 (en) 2016-01-12
MA32369B1 (fr) 2011-06-01
EP2282636B1 (en) 2016-03-23
SI2282636T1 (sl) 2016-06-30
US20170073341A1 (en) 2017-03-16
EP2282636A4 (en) 2012-06-13
JO3408B1 (ar) 2019-10-20
AU2009244491B2 (en) 2014-08-07
HK1147907A1 (zh) 2011-08-26
US8415345B2 (en) 2013-04-09
CL2009001065A1 (es) 2010-12-31
CN102083312B (zh) 2014-08-27
BRPI0912541B1 (pt) 2021-05-11
DOP2010000326A (es) 2010-12-15
IL209018A (en) 2015-08-31
KR20110013456A (ko) 2011-02-09
SG190624A1 (en) 2013-06-28
TW200951130A (en) 2009-12-16
CO6321189A2 (es) 2011-09-20
CA2723396A1 (en) 2009-11-12
UA103319C2 (en) 2013-10-10
US20140080851A1 (en) 2014-03-20
US20130144055A1 (en) 2013-06-06
ES2576684T3 (es) 2016-07-08

Similar Documents

Publication Publication Date Title
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
CO6511251A2 (es) Compuestos quimicos
EA201170227A1 (ru) Имидазолкарбоксамиды
CY1113386T1 (el) Αναστολεις πρωτεασωματος
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
ECSP10010722A (es) Compuestos orgánicos
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1112095T1 (el) Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201000258A1 (ru) Новые гербициды
UA106880C2 (uk) Нові гербіциди